Zymeworks BC Inc

+0.09 (+1.44%)
6:06:51 PM EDT: $6.34 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)440.40M
Current PE2.37
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$14.37 Million
Adjusted EPS-$0.47
See more estimates
10-Day MA$6.47
50-Day MA$7.19
200-Day MA$8.28
See more pivots

Zymeworks BC Inc Stock, NASDAQ:ZYME

108 Patriot Drive, Suite A, Middletown, Delaware 19709
Phone: +1.302.274.8744
Number of Employees: 294


Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab�s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.